Send me real-time posts from this site at my email
Motley Fool

Why Altimmune Stock Is Perking Up Today

What happened

Shares of the developmental stage biotech Altimmune (NASDAQ: ALT) jumped by as much as 17.8% in pre-market trading Tuesday morning. The biotech's shares are perking up this morning in response to the pre-publication of an animal study for its intranasal COVID-19 vaccine candidate known as AdCOVID.

The manuscript is currently available on the pre-print biology server BioRxiv.org. Altimmune is developing AdCOVID in conjunction with the University of Alabama at Birmingham.

Image source: Getty Images.

So what

Altimmune believes AdCOVID could sport several key advantages over the vast array of other COVID-19 vaccines in development. Beyond its unique intranasal administration, the company has designed AdCOVID to be effective in a single dose, to illicit a broad immune response, and to able to be shipped and stored without extensive protocols.

The big deal is that a safe and effective COVID-19 vaccine -- especially one that can be shipped globally with ease -- could be an enormous revenue generator. So while Altimmune is well behind the leaders in the COVID-19 vaccine race, its novel vaccine candidate may indeed be worth keeping tabs on.

Now what

Altimmune plans to file the regulatory paperwork and subsequently begin human trials with AdCOVID in the fourth quarter of 2020. If all goes well, the company may have a shot at bringing this intranasal vaccine to market by 2022.

The bad news is that there will more than likely be multiple COVID-19 vaccines on the market before the end of 2021. That doesn't mean AdCOVID won't be able to carve out a profitable niche, but it will probably face some rather tough competition, to put it mildly.

10 stocks we like better than ALTIMMUNE INC
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and ALTIMMUNE INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Source

Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue